Saturday 17 October 2026
Export TOVX’s income statement to Excel — free account
Theriva Biologics, Inc.
TOVX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.4%, free cash flow grew 34.7% and total debt fell 1.16%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.21
0.00
0.00%
Follow TOVX
Theriva Biologics, Inc. (TOVX) P/E ratio
As of 16 October 2026, Theriva Biologics, Inc. (TOVX) trades at a P/E ratio of 0.1×. Over the past ten years it has ranged from 0.0× (June 2026) to 0.4× (October 2025); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.4×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BIVI BioVie Inc. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| BLRX BioLineRx Ltd. compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| VTGN VistaGen Therapeutics, Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| TOVX Theriva Biologics, Inc. | 0.1× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)